240 / 1241
Slide 23
Risk consideration:
out field recurrence vs. local control
>> 50% risk of local progression
in advanced NSCLC
possible improvement by dose
escalation
must be weighed against
< 10% residual risk of out field
recurrence from microscopic
nodal spread if no ENI
→ Clinical studies!
Saunders R&O 1999